畢馬威:上市改革三週年113宗新經濟IPO共籌集6,963億元
畢馬威發表今年上半年IPO市場回顧,期內香港有46宗上市,集資額按年升130%至2,132億元,主要受中概股迴流所推動。該行中國香港新經濟市場及生命科學主管合夥人朱雅儀表示,期內十大集資額新股中有4只爲TMT行業,包括快手(01024.HK)、百度(09888.HK)(BIDU.US)、嗶哩嗶哩(09626.HK)(BILI.US)及美股Bumble(BMBL.US),三家都在香港上市,預期中概股迴流仍爲未來幾年大趨勢。
她指出,聯交所上市改革已實施三年,過去三年共有113家新經濟行業相關公司上市,集資6,963億元,佔期內新股集資總額60%。2018年下半年至今年上半年共有50家生物科技公司上市,集資1,519億元;第二上市有14宗,集資2,956億元;同股不同權則有12宗,集資3,499億元。
畢馬威中國資本市場諮詢組合夥人劉大昌指出,上半年香港於全球市場中排名第三,僅次於美國納斯達克交易所及紐交所,考慮到目前市場排隊上市企業衆多,有效申請創新高達160宗,因此預測全年香港新股集資額將不少於4,000億元,爭取保持全球第三位。
問及香港推行SPAC的可行性,他預期諮詢文件將於第三季推出,初期料不會完全套用美國模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.